mAChR4

mAChR4/M4 muscarinic acetylcholine receptor is a GPCR that couples mainly to Gαi/o, inhibits adenylate cyclase, and lowers intracellular cAMP signaling[1]. In striatal neurons, M4 signaling restrains dopamine D1 receptor-mediated locomotor stimulation and supports inhibitory cholinergic control over dopamine-dependent behavior[2]. Mechanistically, endogenous cholinergic signaling through M4 receptors in direct-pathway striatal projection neurons promotes corticostriatal long-term depression by suppressing RGS4 activity and blocking D1-dependent long-term potentiation[3]. In disease models, enhancing M4 signaling corrected striatal plasticity deficits in L-DOPA-induced dyskinesia models, supporting M4 as a practical target for basal ganglia circuit studies[3]. Compared with related muscarinic isoforms, M1 and M4 crystal structures bound to tiotropium revealed differences in orthosteric and allosteric binding sites that contribute to subtype-selective drug design[4]. For experimental applications, M4 positive allosteric modulators potentiate acetylcholine responses without directly activating the receptor and showed antipsychotic-like activity in preclinical schizophrenia-relevant assays[5]. Xanomeline further demonstrates ligand complexity at human M4 because structural and pharmacological validation identified dual orthosteric and allosteric binding behavior[6].